Skip to main content

ASKA Pharmaceutical Holdings Long-Term Vision

Toward a Specialty Healthcare Company
Based in Japan,
Pioneering the Future Globally

  • FY2035 Net Sales

    ¥150.0billion
  • Operating Profit Margin

    15%

Long-Term Vision ASKA VISION 2035

Women’s Healthcare Growth Market

Building on Our Strengths in the Hormone Field,
Toward the Next Stage

ASKA Pharmaceutical Holdings
Long-Term Vision
「ASKA VISION 2035」

Women’s Healthcare Market

Women’s healthcare market (contraception, infertility, and women’s disease-related fields) expanding at an average annual rate of approximately 3.3%*
Growth Area with Significant Unmet Needs

Women’s Healthcare Market Graph

Source: Fuji Keizai Co., Ltd. “Latest Trends and Future Outlook of the Contraception, Infertility, and Women’s Disease-Related Market” Unauthorized reproduction prohibited.
*CAGR: approximately 3.3% (2024: ¥128.6 billion – 2035 forecast: ¥184.1 billion)

Our Strengths

Our Group’s Competitive Strengths

Why ASKA Is the Partner of Choice
in This Growth Area

  • Deep Expertise
    in the Hormone Field

    • More than 100 years of specialized experience in the hormone field
    • One of the leading market positions in Japan in the obstetrics & gynecology and thyroid fields
  • Long-Established
    R&D Platform

    • An integrated R&D structure covering the entire process from basic research to commercialization
    • Continuous pipeline creation through a combination of in-house drug discovery and strategic licensing/acquisition
  • Stable
    Revenue Model

    • A diversified revenue structure supported by multiple products and businesses, without dependence on any single product
    • A business model focused on specialty areas, making it less susceptible to drug price revisions and changes in market conditions

Growth Strategy

Growth Strategy

Strengthening existing businesses while expanding into new areas
— from Japan to the global market

Five Pillars Driving Growth

  • Domestic Pharmaceutical

    Addressing sexual health challenges and leading the way toward a healthier society.

  • Drug Discovery

    Advancing the launch of in-house developed products, pipeline expansion, and overseas out-licensing through ASKA’s unique drug discovery platform.

  • Global

    Creating value in specialty fields and strengthening our presence in global markets, primarily in Asia.

  • Animal Health

    Contributing to the realization of sustainable animal health through unique products and solutions.

  • Testing and
    Around-the-Pill

    Contributing to total healthcare through prevention, testing/diagnosis, treatment, and prognosis management utilizing diagnostics and medical devices.

Roadmap to 2035 Targets

Milestones

  1. Net Sales

    ¥71.1 billion

    Operating Margin

    8.2 %

    FY2025

  2. Mid-Term Management Plan2028

    FY2026-2028

    Net Sales

    ¥85.0 billion

    Operating Margin

    10 %

    FY2028

    Deepening core strengths for sustainable growth and
    building a business foundation to support global expansion

  3. Mid-Term Management Plan2031

    FY2029-2031

    Net Sales

    ¥100.0 billion

    Operating Margin

    12 %

    FY2031

    Expanding into new disease areas and establishing
    a foundation for global expansion

  4. Mid-Term Management Plan2035

    FY2032-2035

    Net Sales

    ¥150.0 billion

    Operating Margin

    15 %

    FY2035

    Establishing a strong presence in global markets through
    the integration of in-house developed products and group synergies

Toward 2035 Targets

Roadmap

Mid-Term Management Plan2028

FY2026-2028

Mid-Term Management Plan2031

FY2029-2031

Mid-Term Management Plan2035

FY2032-2035

Domestic Pharmaceuticals

  • Aim for further growth as a leading company in women's health
  • Enter into new therapeutic areas
  • In addition to women's health, tackle men's health-related diseases
  • Raise our presence in new therapeutic areas
  • Become a leading company in solving health issues specific to women and to men

Drug Discovery

  • Construct a drug discovery platform that forms a unique strength in the field of gynecology
  • Aim to be a specialty pharma company in the field of gynecology and promote collaboration and partnerships with pharmaceutical companies in Japan and overseas
  • Build the foundation for early-stage out-licensing of drug discovery seeds
  • Make progress in expanding market launches, pipeline, and overseas out-licensing for in-house discovered compounds

Global

  • Build a business foundation for Hataphar and MedChoice
  • Expand operations at Hataphar's new factory and its product lineup
  • Raise our presence as a specialty pharma company in Southeast Asia, primarily in Vietnam and the Philippines
  • Demonstrate a global presence in specialty areas

Animal Health

  • Expand the market for companion animal and livestock products
  • Tackle new challenges to expand distribution channels
  • Aim to be an industry-leading company in the field of endocrinology
  • Develop overseas markets, primarily in Asia
  • Achieve greater livestock production efficiency and pet well-being through competitive and unique products and solutions

Testing and
Around-the-Pill

  • Promote collaboration with business partners, centered on business utilizing trace analysis technologies
  • Enhance testing related to sex and aging
  • Create new value through collaboration between our proprietary technologies and business partners
  • Contribute to the achievement of a healthy and sustainable society through innovative testing, medical devices, etc

ありたい姿

2035

Aspiring Vision

Aspiring Vision 2035

Purpose
We will realize a healthy tomorrow
and future for all lives
Vision
Toward a Specialty Healthcare Company
Based in Japan,
Pioneering the Future Globally

Long-Term Vision

ASKA Pharmaceutical Holdings Long-Term Vision
ASKA VISION 2035

ASKA VISION 2035
Toward a Specialty Healthcare Company
Based in Japan,
Pioneering the Future Globally